Department of Allergy and Clinical Immunology, Centro Médico-Docente La Trinidad, Carretera La Trinidad-El Hatillo, Caracas, Venezuela.
Immunol Allergy Clin North Am. 2013 May;33(2):251-62. doi: 10.1016/j.iac.2012.10.004. Epub 2012 Oct 31.
It has been recognized that a high proportion of chronic urticaria patients experience symptom aggravation when exposed to aspirin and NSAIDs. This clinical picture is known as Aspirin-exacerbated cutaneous disease. The pathogenesis of these exacerbations is related to the inhibition of cyclooxygenase-1 leading to a decreased synthesis of PGE2 and an increased cysteinyl leukotriene production in the skin and subcutaneous tissues. Patient management comprises the treatment of the underlying cutaneous disease with nonsedating antihistamines and other medications, avoidance of COX-1 inhibitors, and the use of alternative NSAIDs that do not inhibit COX-1 for the relief of pain, inflammation and fever.
已经认识到，很大一部分慢性荨麻疹患者在接触阿司匹林和 NSAIDs 时会出现症状加重。这种临床表现被称为阿司匹林加重的皮肤疾病。这些加重的发病机制与环氧化酶-1 的抑制有关，导致前列腺素 E2 的合成减少和皮肤及皮下组织中半胱氨酰白三烯的产生增加。患者管理包括使用非镇静性抗组胺药和其他药物治疗基础皮肤疾病，避免使用 COX-1 抑制剂，以及使用不抑制 COX-1 的替代 NSAIDs 来缓解疼痛、炎症和发热。
